Altamira Therapeutics

Switzerland
Breíl, Grisons, Switzerland, 4001

Company profile

Altamira Therapeutics company profile

Altamira Therapeutics is dedicated to developing novel pharmaceutical therapies to protect hearing, silence tinnitus, and restore balance. Altamira Therapeutics is the leading pioneer in the emerging field of therapies for neurotologic disorders affecting the inner ear.

Business identity

Contact email
[email protected]
Phone number
+41 61 201 13 50
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
2003-04-01

Headquarters

Postal code
4001
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$114M
Last funding
Post IPO Equity / $4M / 2024-09-17
Last equity funding
Post IPO Equity / $4M
Investors
6
Lead investors
3
Founders
1
Articles
85
Exited on
2014-08-11

Founders and investors

Founders

Thomas Meyer

Lead investors

Idinvest PartnersSofinnova InvestmentsSofinnova Partners

Investors

Hercules CapitalIdinvest PartnersSofinnova InvestmentsSofinnova PartnersZKB Pharma Vision Fund